Claris Lifesciences Consolidated Q1FY16 PAT Rises 31%

Claris Lifesciences Ltd. (CU) today announced its Un-Audited Financial Results for the quarter ended 30th June 2015 at its board meeting held at its registered office in Ahmedabad.

Claris Lifesciences Limited (BSE Code: 533288) the Company with three segmental revenues, (i) the Speciality Injectables Business which is housed in a wholly owned subsidiary; Claris Injectables Limited, (ii) 20% stake in the Joint Venture with Otsuka and Mitsui for the Infusion Business in India and Emerging Markets, and (iii) the Treasury and Cash management for the funds in the Holding Company.

Key financial highlights of the Specialty Injectable Business:

• Net Sales for Q1FY15 stood at Rs. 1,459 mn, which has grown by around3l% as compared to the previous quarter.
• EBITDA has grown by 29%; to Rs. 520 mn; over the previous quarter.
• EBITDA margins for the quarter stood at 36%, in line with the margins for the previous quarter.
• Net Profit for the quarter stood at Rs. 208 mn the Profit during the previous quarter stood at Rs. 182 mn, showing a growth of 14% quarter on quarter.
• Assuming this quarter will account for around 25% of the full year sales, the speciality injectables business can be expected to achieve around Rs. 5,800 mn of sales for FY2016.